Amivantamab + lazertinib (first-line EGFR NSCLC)

This combination pairs amivantamab, a bispecific antibody against EGFR and MET, with lazertinib, an oral EGFR inhibitor, as first-line treatment for EGFR-mutant non-small-cell lung cancer. Lazertinib blocks EGFR signalling from inside the cell while amivantamab blocks EGFR and MET at the cell surface and recruits immune effectors, so the pairing pre-empts the two main escape routes from osimertinib, MET amplification and the C797S mutation. The phase 3 MARIPOSA trial compared it with osimertinib and showed a progression-free and overall survival benefit. The price is more toxicity, including rash, paronychia, venous thromboembolism and infusion reactions, plus intravenous visits; subcutaneous amivantamab, introduced in 2025, eases the latter.